NYSE · CIK 0001471727
SRXH SRx Health Solutions, Inc.
Insider trading from SEC Form 4. Last filing Oct 7, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
2
with a Form 4 at this company
Signals
Open-market buys and sells at SRx Health Solutions, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Lionel F. Conacher director buy | $227k 30,463 shares | +450% | - | |
| 15Weak | Lionel F. Conacher director sell | $1,086 635 shares | -2% | - |
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 25, 2025 | David Allan White director | AGrant or award Common Stock | +154,128 | $0.40 | $62k | 344,975 | Oct 7, 2025 |
| May 1, 2025 | David Allan White director | AGrant or award Common Stock | +1,463 | $1.23 | $1,799 | 190,847 | Oct 7, 2025 |
| Apr 24, 2025 | David Allan White director | AGrant or award Common Stock | +183,184 | $2.09 | $383k | 189,384 | Oct 7, 2025 |
| Apr 24, 2025 | David Allan White director | AGrant or award Common Stock | +6,200 | $2.09 | $13k | 6,200 | Oct 7, 2025 |
| Jul 7, 2025 | David Allan White director | POpen-market purchase Common Stock Purchase Warrantderivative | +69,732 | $0.62 | $43k | 69,732 | Oct 7, 2025 |
| Dec 23, 2024 | Lionel F. Conacher director | SOpen-market sale Common Stock | -635 | $1.71 | $1,086 | 36,597 | Dec 26, 2024 |
| Nov 20, 2024 | Lionel F. Conacher director | POpen-market purchase Common Stock | +5,000 | $1.71 | $8,550 | 37,232 | Dec 26, 2024 |
| Feb 1, 2024 | Lionel F. Conacher director | POpen-market purchase Common Stock | +8,418 | $11.88 | $100k | 32,232 | Dec 26, 2024 |
| Sep 5, 2023 | Lionel F. Conacher director | POpen-market purchase Common Stock | +17,045 | $6.97 | $119k | 23,814 | Dec 26, 2024 |
| Jun 26, 2024 | Lionel F. Conacher director | POpen-market purchase Stock Options - Right to Buyderivative | +0 | $5.00 | $0 | 5,200 | Dec 26, 2024 |
| Sep 28, 2021 | Lionel F. Conacher director | POpen-market purchase Stock Options - Right to Buyderivative | +0 | $159.28 | $0 | 615 | Dec 26, 2024 |
| Nov 20, 2024 | Lionel F. Conacher director | AGrant or award Common Stock | +5,000 | $1.78 | $8,900 | 37,232 | Nov 27, 2024 |
| Feb 1, 2024 | Lionel F. Conacher director | AGrant or award Common Stock | +8,418 | $0.27 | $2,273 | 32,642 | Nov 27, 2024 |
| Sep 5, 2023 | Lionel F. Conacher director | AGrant or award Common Stock | +17,045 | $0.00 | $0 | 24,224 | Nov 27, 2024 |
| Jun 26, 2024 | Lionel F. Conacher director | AGrant or award Stock Options - Right to Buyderivative | +0 | $5.00 | $0 | 5,200 | Nov 27, 2024 |
| Sep 28, 2021 | Lionel F. Conacher director | AGrant or award Stock Options - Right to Buyderivative | +0 | $3.62 | $0 | 615 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Lionel F. Conacherdirector, ceo, officer
- David Allan Whitedirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.